Steven Seedhouse
Stock Analyst at Raymond James
(3.36)
# 968
Out of 4,983 analysts
176
Total ratings
43.86%
Success rate
4.71%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics | Reiterates: Outperform | $56 → $63 | $39.10 | +61.13% | 4 | Sep 9, 2025 | |
| KRRO Korro Bio | Maintains: Strong Buy | $153 → $147 | $32.12 | +357.66% | 3 | Aug 13, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $73.48 | +11.60% | 20 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $6.92 | +44.51% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $24.48 | +14.38% | 1 | Apr 29, 2025 | |
| ATXS Astria Therapeutics | Initiates: Overweight | $47 | $7.65 | +514.38% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $1.14 | +777.19% | 14 | Apr 29, 2025 | |
| BCRX BioCryst Pharmaceuticals | Initiates: Overweight | $20 | $7.76 | +157.90% | 1 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $23.67 | +339.37% | 20 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $1.86 | +1,084.58% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $53 → $49 | $8.07 | +507.19% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $6 → $14 | $2.05 | +582.93% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $111.63 | -16.69% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $24.89 | +173.20% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $23.91 | +343.33% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $6.42 | +133.83% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $13.49 | +315.12% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $0.31 | +5,537.89% | 8 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $12.97 | +339.48% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $1.92 | +1,045.83% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $2.79 | +509.32% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $3.24 | +980.25% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $50.03 | -24.05% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $41.55 | +70.88% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $3.12 | +60.26% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $20.00 | +90.00% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $17.93 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.52 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $12.81 | +2,007.73% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $144.95 | - | 2 | Apr 23, 2020 |
Dianthus Therapeutics
Sep 9, 2025
Reiterates: Outperform
Price Target: $56 → $63
Current: $39.10
Upside: +61.13%
Korro Bio
Aug 13, 2025
Maintains: Strong Buy
Price Target: $153 → $147
Current: $32.12
Upside: +357.66%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $73.48
Upside: +11.60%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $6.92
Upside: +44.51%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $24.48
Upside: +14.38%
Astria Therapeutics
Apr 29, 2025
Initiates: Overweight
Price Target: $47
Current: $7.65
Upside: +514.38%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $1.14
Upside: +777.19%
BioCryst Pharmaceuticals
Apr 29, 2025
Initiates: Overweight
Price Target: $20
Current: $7.76
Upside: +157.90%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $23.67
Upside: +339.37%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $1.86
Upside: +1,084.58%
Nov 8, 2024
Maintains: Strong Buy
Price Target: $53 → $49
Current: $8.07
Upside: +507.19%
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $2.05
Upside: +582.93%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $111.63
Upside: -16.69%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $24.89
Upside: +173.20%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $23.91
Upside: +343.33%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $6.42
Upside: +133.83%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $13.49
Upside: +315.12%
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $0.31
Upside: +5,537.89%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $12.97
Upside: +339.48%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $1.92
Upside: +1,045.83%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $2.79
Upside: +509.32%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $3.24
Upside: +980.25%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $50.03
Upside: -24.05%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $41.55
Upside: +70.88%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $3.12
Upside: +60.26%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $20.00
Upside: +90.00%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $17.93
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.52
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $12.81
Upside: +2,007.73%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $144.95
Upside: -